The innovative approach from anavo medical tackles the persistent challenge of chronic wounds in modern medicine, exacerbated by conditions like diabetes and the rise of antibiotic-resistant bacteria. Through collaboration with experts at ETH Zurich and Empa St. Gallen, their nanoparticles mimic human enzymes to promote healing by reducing inflammation, eradicating microbes, and stimulating tissue regeneration directly at the wound site. This advancement in wound care technology offers patients a faster recovery with reduced risk, addressing a critical need in healthcare. Tino Matter is the Co-Founder & CEO and participated in the program 2022.
